Lucid Diagnostics Announces Pricing of Initial Public Offering
13. Oktober 2021 22:15 ET
|
Lucid Diagnostics Inc.
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:...
PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
10. Juni 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its...
Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies
24. Mai 2021 09:30 ET
|
PAVmed Inc.
Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) --...
PAVmed Provides Business Update and First Quarter 2021 Financial Results
17. Mai 2021 16:00 ET
|
PAVmed Inc.
Conference call to be held today at 4:30 PM EDT NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product,...
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
22. Februar 2021 08:18 ET
|
PAVmed Inc.
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its...
Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor
15. Juni 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical...
PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones
07. November 2019 09:30 ET
|
PAVmed Inc.
Unprecedented six-month maintenance-free implant duration achieved FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK,...
PAVmed to Hold Business Update Conference Call on November 21, 2019
06. November 2019 09:30 ET
|
PAVmed Inc.
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
05. November 2019 07:00 ET
|
PAVmed Inc.
Extends cash runway to support multiple milestones including commercialization of two lead products NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...
PAVmed to Hold Business Update Conference Call on September 5, 2019
07. August 2019 09:30 ET
|
PAVmed Inc.
NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...